Merritt, Kate http://orcid.org/0000-0002-5716-4941
Perez-Iglesias, Rocio
Sendt, Kyra-Verena
Goozee, Rhianna
Jauhar, Sameer
Pepper, Fiona
Barker, Gareth J
Glenthøj, Birte
Arango, Celso
Lewis, Shôn
Kahn, René
Stone, James http://orcid.org/0000-0003-3051-0135
Howes, Oliver
Dazzan, Paola
McGuire, Philip
Egerton, Alice
Funding for this research was provided by:
Brain and Behavior Research Foundation (YIA 2012–18777, YIA 2012–18777)
European Commission (HEALTH-F2-2010-242114, HEALTH-F2-2010-242114)
RCUK | Medical Research Council (MC-A656-5QD30)
Wellcome Trust (094849/Z/10/Z)
Article History
Received: 16 March 2019
Accepted: 19 June 2019
First Online: 1 August 2019
Competing interests
: A.E. has received research funding from Roche and consultancy payment from Heptares Therapeutics. P.M. has received consultancy payment for Sunovion and Takeda. R.P.I. has received honoraria as a speaker for Lundbeck. O.H. has received speaker bureau honoraria and charitable reseach funding from AstraZeneca, BMS, Eli Lilly, Jannsen-Cilag, and Roche. G.J.B. has received honoraria for teaching from General Electric Healthcare. B.G. is the leader of a Lundbeck Foundation Centre of Excellence for Clinical Intervention and Neuropsychiatric Schizophrenia Research (CINS), which is partially financed by an independent grant from the Lundbeck Foundation based on international review and partially financed by the Mental Health Services in the Capital Region of Denmark, the University of Copenhagen, and other foundations. B.G. has also received a research grant from Lundbeck A/S for another independent investigator-initiated study. All grants are the property of the Mental Health Services in the Capital Region of Denmark and administrated by them. The remaining authors declare no competing interests.